Inimmue is a promising new biotechnology company founded by pharmaceutical industry veterans, focused on developing the next generation of immunotherapeutics. The group has extensive expertise in synthetic and process chemistry, drug formulation and immunology. Our pipeline currently includes several compounds and formulations thereof that modulate the innate immune system through Toll-like Receptors 4 and 7/8. Current preclinical programs are developing these assets for use in areas of critical patient need such as food allergy, allergic rhinitis, autoimmunity, as well as topically in cancer. Additionally, Inimmune applies its collective 50 years expertise in preclinical drug development to offer various contract services. Inimmune was founded in early 2016. It is located in Missoula, MT and works in close collaboration with the Center for Translational Medicine at the University of Montana as well as several industry and several academia and industry partners.
